Institutional Buying and Insider Selling: The Incyte Investment Conundrum

A notable divergence has emerged in the trading activity surrounding biotech firm Incyte. The stock is climbing toward new peaks, propelled by substantial institutional accumulation. This surge, however, occurs alongside a steady stream of share sales by the company’s own executives, presenting investors with a complex puzzle to decipher.

Recent regulatory disclosures reveal aggressive buying from two major investment firms, signaling strong institutional conviction. Federation des caisses Desjardins du Quebec dramatically increased its stake by a remarkable 368.8%, bringing its total holdings to 47,091 shares. In an even more substantial move, Jacobs Levy Equity Management demonstrated its confidence by acquiring an additional 506,484 shares. This purchase, valued at $84.7 million, expands the fund?s total position to 1.4 million shares. Concentrated acquisitions of this magnitude Read more...

de | US45337C1027 | INSTITUTIONAL | boerse | 68167022 |